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Abstract 
Introduction: Increasing numbers of patients with breast cancer receive neoadjuvant therapies. We investigated 
differences in survival rates between geriatric and non-geriatric patient groups following administration of 
neoadjuvant therapies. Materials and Method: We examined 166 patients who received neoadjuvant therapy for breast 
cancer between 2007 and 2016. Patients <70 years were in Group 1 and those ≥70 years were in Group 2. We 
retrospectively compared age, sex, treatment, tumour stage and localisation, status of oestrogen and progesterone 
receptors, involvement of axillary lymph nodes, systemic treatment complications, treatment compliance and survival 
rates using a variety of parametric and non-parametric statistical tests. Results: The mean ages of patients in Group 1 
(n = 136) and Group 2 (n = 30) were 44.6 ± 8.92 and 76.7 ± 5.48 years, respectively. The most common tumour 
location was the upper-outer quadrant. All patients received treatment consisting of 4AC (doxorubicin-
cyclophosphamide) + 4 taxane or 4AC (doxorubicin-cyclophosphamide) + paclitaxel for 12 weeks. Neither group 
exhibited mortality or complications requiring treatment interruption. Breast-conserving surgery was performed in 88 
(53%) patients. Complete response was achieved in 14 (8%) patients after surgery. Mean tumour diameters in Groups 
1 and 2 were 26.8 mm (±27.59) and 28.5 mm (±40.23), respectively. Five-year general survival rates were %69,7 in 
Group 1 and % 70 in Group 2( p = 0.94). Conclusion: Neoadjuvant therapy is a reliable treatment option in patients 
≥70 years who are candidates for chemotherapy, since complication and mortality rates did not increase compared 
with younger patients. 
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Introduction 
 
 
For females in both developed and developing countries, 
breast cancer has the second highest mortality rate after 
lung cancer. More than 1.3 million individuals are 
diagnosed with breast cancer each year, and the 
mortality rate is 60% in developing countries [1-2]. 
Some studies have reported that in American women, 
the probability of developing breast cancer is 12.3% [3]. 
Presently, various factors such as genetic predisposition, 
hormones, lifestyle and age play an etiological role in 
this disease [4]. 
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Approximately 7% of patients with breast cancer are 
diagnosed before age 40 years [5] and the risk for breast 
cancer increases with age.  
The most critical factors affecting the survival of 
patients with breast cancer are early diagnosis, tumour 
stage and age [3,6,7]. Neoadjuvant therapy can reduce 
tumour size and may provide a higher chance for breast-
conserving surgery (BCS). Additionally, and perhaps 
more importantly, achieving pathological complete 
response of 50%–60% in axillary-positive patients may 
allow the performance of sentinel node biopsy instead 
of axillary dissection in patients with axillary 
downstage. Thus, lymphoedema due to axillary 
dissection, restricted shoulder range of motion, 
numbness and reduced quality of life are potentially 
prevented. Also, treatment modification may be 
performed by in vivo monitoring of chemotherapeutic 
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responses of an existing tumour. Studies report high 
rates of pathological complete responses and, 
consequently, remarkable survival advantages in 
patients who received  neoadjuvant therapy 
Consequently, neoadjuvant therapy appears to be a good 
treatment option for some patients as it increases the 
chances that BCS (rather than mastectomy) can be 
performed by reducing tumour size [2,5-7]. This less 
drastic, surgical approach holds both psychological and 
cosmetic advantages [4].In Literacy prognosis of 
premenopausal patients with breast cancer was worse 
than that of postmenopausal females.[8] Despite these 
findings, administration of neoadjuvant therapies 
associated with favourable outcomes in younger patients 
is generally considered more deliberately in elderly 
patients (2,9). Various studies on the effects of 
neoadjuvant therapy have been conducted; however, 
these focused on patients <65 years [10,11], and there 
are little outcomes data pertaining to neoadjuvant 
therapy in older patients. We sought to investigate 
differences in survival rates between geriatric and non-
geriatric patient groups following administration of 
neoadjuvant therapies for breast cancer. 
Materials and Method 
Study profile and data collection 
We retrospectively analysed patients who were followed 
up between 2007 and 2016. Patients <70 years old were 
designated as Group 1 and those ≥70 years were Group 
2. This study was approved by the Istanbul University 
Ethical Committee approval. 
Patient characteristics 
Patients were treated with the following protocol: 4AC 
(doxorubicin-cyclophosphamide) + 4 taxane or 4AC 
(doxorubicin-cyclophosphamide) + paclitaxel for 12 
weeks. Patients were followed for hematologic toxicity 
(neutropenia, thrombocytopenia), hepatic toxicity, 
nephrotoxicity, nausea and vomiting associated with 
chemotherapy drugs, deterioration of the general 
condition of the patient, decrease in functional capacity 
during treatment. Routine clinical and radiological 
examinations (mammography, breast ultrasound and 
breast magnetic resonance imaging) were completed 
prior to and following treatment to determine treatment 
response. Herceptin was added to the treatment regimen 
of HER2-positive patients. HER 2 positive patients took 
Trastuzumab during neodjuvan therapy and after the 
surgery.  
Statistical analysis 
Study data were evaluated using descriptive statistical 
methods, such as averages, standard deviations, 
frequencies and percentages, whereas variable 
distributions were assessed using the Kolmogorov–
Smirnov test. Student’s t-tests and Mann–Whitney U-
tests were used to analyse quantitative data while 
qualitative data were analysed using the Chi-square test. 
Kaplan–Meier analysis was used to determine survival 
rates, and the log-rank test was used to perform 
comparisons. SPSS 24.0 software was used in the 
analysis of study data. The level of statistical 
significance was accepted as p < 0.05. 
Results 
Our study included 166 patients. Group 1 (<70 years) 
consisted of 136 patients, whereas Group 2 (≥70 years) 
consisted of 30 patients. The mean age of the study 
group was 49.50 ± 13.42 (26–89) years. Breast tumour 
was most commonly found in the right breast and upper-
outer quadrant. BCSs were performed in 88 patients. 
Demographic data are shown in Table 1. 
Table 1: Demographic data 
 Group 1 <70 Group 2 ≥70 p 
Mean age 44.60 ± 8.92 76.73 ± 5.48 0,005 
Mean ASA  1.13 ± 0.34 2.4 ± 0.81 <0.001 
Presence of comorbidity 19 30  
 N % n %  
Operation BCS 73 53.7 15 50 0.434 
Mastectomy 63 46.3 15 50 
Quadrant Lower outer 19 14 6 20 0.960 
Lower inner 14 10.3 3 10 
Upper outer 57 41.9 12 40 
Upper inner 18 13.2 3 10 
Overlapping 11 8.1 3 10 
Central  17 12.5 3 10 
Pathological  regression 
rate 
 65.89 ± 32.9  68 ± 34.87  0.557 
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ASA: American Society of Anesthesiologists classification BCS: Breast conserving surgery 
One hundred and thirty-nine patients were administered 
the 4AC-4T treatment regimen, and no statistically 
significant difference was found between the results of 
the administered treatment regimens (p > 0.05). In the 
content of these treatment regimens, 4AC + 12p 
treatment protocol was performed instead of 4AC + 4T 
in elderly patients. Pathological  regression rates were 
66% and 68% in Groups 1 and 2 patients, respectively 
(p>0.05). There were no differences between the clinical 
stages of patients prior to chemotherapy. Pathological 
examination revealed no tumour in 20 patients who 
underwent surgery after neoadjuvant therapy. The 
patients most commonly received surgery during the 
cT2 stage. Pathological complete response rates (pCRs) 
were 8% in Group 1 patients and 30% in Group 2 
patients (p=0.01). (Table 2)  
Table 2: Postoperative stages 
 Group 1 <70 Group 2 ≥70 p 
n % n % 
T stage 0 11 8.1 9 30 0.01 
1 12 8.8 3 10 
2 59 43.4 6 20 
3 38 27.9 9 30 
4 16 11.8 3 10 
N stage 0 24 17.6 12 40 0.001 
1 84 61.8 15 50 
2 25 18.4 0 0 
3 3 2.2 3 10 
In Group 1, 81 patients (59%) were oestrogen receptor-
positive and 59 (43%) were progesterone receptor-
positive. In Group 2, 15 patients (50%) were oestrogen 
receptor-positive and three patients (10%) were 
progesterone receptor-positive (p = 0.224 and p = 0.001, 
respectively). Lymphovascular invasion was found in 69 
patients (Table 3). 
Table 3: Pathological data 
 Group 1 <70 Group 2 ≥70 p 
Residual Tumour Size 26.81 ± 27.59 28.50 ± 40.23 0.020 
Oestrogen receptor (+) 81 (59%) 15 (50%) 0.224 
Progesterone (+) 59 (43%) 3 (10%) 0.000 
Lymphovascular invasion (+) 57 (41%) 12 (40%) 0.508 
Necrosis (+) 17 (12%) 3 (10) 0.493 
HER2 (+) 17 (12%) 3 (10%) 0.493 
 
No patient died during treatment and there were no 
toxicity events that required the interruption of 
chemotherapy in either group. No differences between 
groups were found in surgical complications 
(hematoma,wound infection and seroma). Mean 
survival duration was 79.103 ± 4.057 (71.152–87.054) 
months. Disease relapse was determined in 24 and 3 
patients in Groups 1 and 2, respectively. Median 45-
month (1–116 months) follow-up revealed disease-free 
survival rates of 92.599 ± 4.22 (Group 1) and 86.500 ± 
5.20 (Group 2; p = 0.184). Five-year overall survival 
rates were  % 69,7 in Group 1 and % 70 in Group 2. An 
evaluation of mean survival rates between the groups 
showed no statistically significant difference, although 
survival rate of Group 1 patients was slightly higher (p 
= 0.94).  
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 Figure 1: Overall survival 
 
 
Figure 2: Disease-free survival 
 
 
 
Discussion 
 
Follow-up and treatment of breast cancer is an important 
public healthcare problem and, despite diagnostic and 
treatment advances, is more complicated in elderly 
patients than in younger patients. Patient age is a critical 
risk factor for breast cancer. A study out of the United 
States of America indicated that geriatric patients 
frequently present with invasive breast cancer. 
Approximately 50% of the new cases were among older 
patients [5,6]. Age 70 is an important cut point for breast 
cancer risk. The risk of developing breast cancer is 
higher in women ≥70 years, and breast cancer treatment 
is a more complicated proposition in this population 
because of comorbidities [5,7,12]. Patients ≥70 years are 
considered “geriatric”; therefore, we sought to compare 
treatment outcomes  
 
 
 
 
 
between patients with breast cancer who were <70 years 
and those aged ≥70 years. 
Survival rates of patients with breast cancer improve 
depending on early diagnosis, treatment model and 
accurate regulation of follow-up visits. Developments in 
early diagnosis and treatment reduced annual mortality 
rates related to breast cancer to <36% [3,12]. Many 
studies that examined survival in patients with breast 
cancer focused on the relationship between survival and 
early diagnosis or tumoural invasion. Studies that 
examined treatment response relative to age were 
usually associated with younger patients; existing data 
on treatment responses among geriatric patients is 
limited [7,12]. The present study contributes novel 
insights to this topic since we analysed responses to 
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neoadjuvant therapy in geriatric patients with breast 
cancer compared with those in younger patients with 
breast cancer. 
Difference in response rates to neoadjuvant therapies 
between younger and older patients is an important 
issue. In our study, pCR was higher in geriatric patients 
than in non-geriatric patients. Tumour biology revealing 
higher PR-negative and higher HER2-positive levels in 
geriatric patients receiving neoadjuvant therapy may 
explain the higher complete response rates. The fact that 
pCR in geriatric patients was not worse than that 
observed in non-geriatric patients is an important 
finding that may support the use of neoadjuvant 
therapies in geriatric patients. 
Adjuvant chemotherapy may not be preferred for use in 
geriatric patients because of concerns including 
medication side effects or the potential for 
chemotherapeutic resistance, which may develop during 
treatment [10,13]. Neoadjuvant therapies should also be 
considered as potential treatments in geriatric patients 
with breast cancer; however, studies on this subject are 
limited. Of note, neoadjuvant therapy increases survival 
rates in addition to its known advantages including 
monitorisation of treatment response. Additionally, 
adjuvant therapy may increase the chance of BCS in 
patients with pCR (10). In our study, the 5-year survival 
rate was 76% in patients who received neoadjuvant 
therapy and 66% in geriatric patients. Although survival 
may vary depending on many factors, our outcomes are 
in agreement with existing literature [2,1,14-16]. 
The term “geriatric oncology” was first suggested in 
2003 and has received increasing attention in recent 
years [17]. According to the WHO data, individuals 
aged 66–79 and 80–99 years are considered of “middle” 
and “elderly” ages, respectively. Even as the human 
lifespan continues to lengthen, the accepted age ceiling 
for neoadjuvant therapy remains 70 years in the current 
common practice. Prior to 1980’s, elderly patients were 
often excluded from studies, whereas outcome data 
increasingly include that of elderly patients [18]. The 
assertion that chemotherapy provides better responses in 
younger patients is inconsistently supported by existing 
data. Some studies report milder side effects of 
chemotherapy in younger than in elderly patients. On the 
other hand, another study found that biological age was 
more important than chronological age when examining 
tolerance to standard chemotherapy in elderly patients. 
According to several studies, elderly patients present to 
oncologists during earlier tumour stages. Distant 
metastases develop more frequently in elderly patients 
than in younger patients with the same tumour stage who 
receive the same treatment [19,20]. This outcome 
suggests that more aggressive therapy may be indicated 
in elderly patients. The treatment protocols set forth by 
the NCCN Oncology Outcomes Database for Breast 
Cancer can be used to minimise toxicity; however, 
cancer treatment should be individualised. During the 
decision-making process, the patient’s biological 
characteristics should be taken into account in addition 
to tumour-associated factors [21]. Patient preference is 
another important consideration. Age should not be 
taken as the sole restrictive factor during the decision-
making process. The patient’s biological age, disease 
stage, tumour characteristics, expected response after 
chemotherapy, disease-free survival duration and 
preferences require consideration in addition to the 
chronological age. 
The positive effects of the postmenopausal period on 
treatment also require attention [8,10]. Neoadjuvant 
therapy improves life quality by helping the patient 
psychologically and facilitating adaptation to life 
circumstances. Additionally, it can reduce tumour size, 
thereby helping conserve breast tissue by BCS and 
increasing the chance of cure [5,15,17,22]. Bleyer et al. 
found that younger female patients had a higher chance 
of survival than elderly female patients across all disease 
stages [23]. However, another study found that the rate 
of local relapse after mastectomy was nine-fold higher 
in young female patients than that in elderly female 
patients [9]. All in all, young and elderly patients may 
show different survival rates; however, this can be 
attributed to the biological status of both age groups [5]. 
The outcomes of our study suggest that neoadjuvant 
therapy may provide favourable results not only in the 
treatment of patients with breast cancer aged <70 years 
old but also in geriatric patients ≥70 years. Breast 
preservation may also afford psychological benefits. 
Presently, a commonly preferred neoadjuvant treatment 
regimen without age limit is anthracycline, 
cyclophosphamide and taxane-based chemotherapy 
[10]. We preferred this treatment regimen for most of 
the patients in our study. Besides this regimen, several 
studies reported that administration of weekly paclitaxel 
as a taxane treatment is easier and safer in patients with 
comorbidities. In our study, there were no differences in 
complications that required treatment interruption and in 
treatment responses between the administrations of 
weekly paclitaxel and docetaxel once every 3 weeks 
(p>0.05). Nevertheless, there are many studies which 
have reported that paclitaxel can be administered 
weekly, is well-tolerated and is associated with similar 
response rates in elderly patient with comorbidities. 
In conclusion, geriatric patients with breast cancer who 
received neoadjuvant therapy showed similar treatment 
results compared with non-geriatric patients with breast 
cancer. Since many studies published on this subject 
have shown that there were no differences between the 
outcomes associated with either adjuvant or neoadjuvant 
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therapy, neoadjuvant therapy may help improve the 
quality of life for geriatric patients and should stand as a 
treatment option for these individuals. 
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